Source:http://linkedlifedata.com/resource/pubmed/id/21176115
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-6-29
|
| pubmed:abstractText |
5?-reductase inhibitors (5?-RIs), finasteride and dutasteride, have been approved for treatment of lower urinary tract symptoms, due to benign prostatic hyperplasia, with marked clinical efficacy. Finasteride is also approved for treatment of hair loss (androgenetic alopecia). Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse effects on sexual function, gynecomastia, depression, and quality of life remains ill-defined.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1743-6109
|
| pubmed:author | |
| pubmed:copyrightInfo |
© 2010 International Society for Sexual Medicine.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
872-84
|
| pubmed:meshHeading | |
| pubmed:year |
2011
|
| pubmed:articleTitle |
Adverse side effects of 5?-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
|
| pubmed:affiliation |
Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.
|
| pubmed:publicationType |
Journal Article,
Review,
Case Reports,
Research Support, Non-U.S. Gov't
|